Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Company Overview

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations. Ensysce is advancing ENS100 through preclinical studies and regulatory interactions, with the goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Beyond pain management, the platform underpins additional pipeline programs targeting other central nervous system indications where controlled drug delivery may enhance therapeutic benefit and safety.

Founded with a mission to address critical public health challenges, Ensysce Biosciences operates primarily in the United States and engages in collaborative partnerships to support its research and development activities. The company holds a portfolio of issued patents and pending applications covering its enzyme-activated prodrug technologies, reflecting a commitment to innovation in the design of safer pharmaceutical therapies.

Key Stats

• Today's Range: $2.35 to $2.63
• 50-Day Range: $2.03 to $2.54
• 52-Week Range: $1.62 to $14.67
• Volume: 873,884 shs
• Average Volume: 109,185 shs
• Market Capitalization: $7.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Ensysce Biosciences Stock Analysis - MarketRank™

Ensysce Biosciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Ensysce Biosciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ensysce Biosciences are expected to decrease in the coming year, from ($8.33) to ($12.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ensysce Biosciences is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ensysce Biosciences is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ensysce Biosciences has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.09% of the outstanding shares of Ensysce Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Ensysce Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ensysce Biosciences has recently decreased by 35.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ensysce Biosciences does not currently pay a dividend.

Dividend Growth

Ensysce Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.09% of the outstanding shares of Ensysce Biosciences have been sold short.

Short Interest Ratio / Days to Cover

Ensysce Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ensysce Biosciences has recently decreased by 35.93%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Ensysce Biosciences this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for ENSC on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.90% of the stock of Ensysce Biosciences is held by insiders.

Percentage Held by Institutions

Only 5.63% of the stock of Ensysce Biosciences is held by institutions.

ENSC Stock Analysis - Frequently Asked Questions

How have ENSC shares performed this year?

Ensysce Biosciences' stock was trading at $8.14 at the beginning of 2025. Since then, ENSC stock has decreased by 69.8% and is now trading at $2.46.

How were Ensysce Biosciences' earnings last quarter?

Ensysce Biosciences, Inc. (NASDAQ:ENSC) released its earnings results on Wednesday, August, 13th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.23. The company earned $1.37 million during the quarter, compared to the consensus estimate of $0.67 million. Ensysce Biosciences had a negative trailing twelve-month return on equity of 167.23% and a negative net margin of 88.76%.

When did Ensysce Biosciences' stock split?

Ensysce Biosciences's stock reverse split before market open on Friday, March 31st 2023.The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Ensysce Biosciences?

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ensysce Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENSC
• CIK: 1716947
• Web: ensysce.com
• Phone: 858-263-4196
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.99 million
• Net Margins: -88.76%
• Pretax Margin: -88.78%
• Return on Equity: -167.23%
• Return on Assets: -104.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.10
• Quick Ratio: 2.10

Sales & Book Value

• Annual Sales: $5.21 million
• Price / Sales: 1.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 2,970,000
• Free Float: 2,734,000
• Market Cap: $7.31 million
• Optionable: Not Optionable
• Beta: 1.10